GSK plc (NYSE:GSK) is one of the 11 best European stocks to invest in. On June 24, the company announced receipt of FDA ...

GSK’s approval expands belimumab treatment options, offering a first-of-its-kind subcutaneous option that can be administered ...

The US FDA has approved GSK's 200 mg/ml autoinjector of Benlysta for individuals aged five years and above with active lupus ...

The transcriptional repressor B lymphocyte-induced maturation protein 1 (BLIMP1) is crucial for plasma cell differentiation and is an early marker of plasma cell development.

He, L., Zhou, Y., Wang, Q.T., Liu, J. and Ma, J.P. (2025) Two Pathological Patterns in Different Stages of the Same Disease. Journal of Biosciences and Medicines, 13, 189-195. doi: ...

Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, ...

The US Food and Drug Administration (FDA) has approved the belimumab 200 mg/mL autoinjector for children aged 5 years of older with active lupus nephritis (LN) who are receiving standard therapy.

Whether antiretroviral therapy (ART) is always completely suppressive, or HIV might continue to replicate at low levels despite ART in some people with HIV (PWH), is still debated. Here, we ...

The FDA has approved a 200 mg/mL autoinjector of belimumab (Benlysta) for at-home subcutaneous use in children aged 5 years ...

This article explores the complex roles of cytokine networks in the development and progression of autoimmune diseases.